These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 32653044)

  • 1. Initiating guideline-concordant gout treatment improves arterial endothelial function and reduces intercritical inflammation: a prospective observational study.
    Toprover M; Shah B; Oh C; Igel TF; Romero AG; Pike VC; Curovic F; Bang D; Lazaro D; Krasnokutsky S; Katz SD; Pillinger MH
    Arthritis Res Ther; 2020 Jul; 22(1):169. PubMed ID: 32653044
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Xanthine oxidase inhibitor urate-lowering therapy titration to target decreases serum free fatty acids in gout and suppresses lipolysis by adipocytes.
    Guma M; Dadpey B; Coras R; Mikuls TR; Hamilton B; Quehenberger O; Thorisdottir H; Bittleman D; Lauro K; Reilly SM; Liu-Bryan R; Terkeltaub R
    Arthritis Res Ther; 2022 Jul; 24(1):175. PubMed ID: 35879786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of efficacy and safety of urate-lowering therapies for hyperuricemic patients with gout: a meta-analysis of randomized, controlled trials.
    Fan M; Liu J; Zhao B; Wu X; Li X; Gu J; Schlesinger N
    Clin Rheumatol; 2021 Feb; 40(2):683-692. PubMed ID: 32654080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New Perspectives in Rheumatology: Implications of the Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Morbidities Trial and the Associated Food and Drug Administration Public Safety Alert.
    Choi H; Neogi T; Stamp L; Dalbeth N; Terkeltaub R
    Arthritis Rheumatol; 2018 Nov; 70(11):1702-1709. PubMed ID: 29869840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular Disease in Gout and the Protective Effect of Treatments Including Urate-Lowering Therapy.
    Gupta MK; Singh JA
    Drugs; 2019 Apr; 79(5):531-541. PubMed ID: 30868398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular Safety of Urate Lowering Therapies.
    Kang EH; Kim SC
    Curr Rheumatol Rep; 2019 Jul; 21(9):48. PubMed ID: 31342190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impaired arterial responsiveness in untreated gout patients compared with healthy non-gout controls: association with serum urate and C-reactive protein.
    Krasnokutsky S; Romero AG; Bang D; Pike VC; Shah B; Igel TF; Dektiarev I; Guo Y; Zhong J; Katz SD; Pillinger MH
    Clin Rheumatol; 2018 Jul; 37(7):1903-1911. PubMed ID: 29450849
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Gout management: an update].
    Ankli B; Krähenbühl S
    Ther Umsch; 2016; 73(3):115-24. PubMed ID: 27008442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of appropriate duration of colchicine prophylaxis to maximize the persistence of xanthine oxidase inhibitors as the first-line urate-lowering therapy in patients with gout using the Korean Health Insurance Review and Assessment Service database.
    So MW; Kim AR; Lee SG
    Int J Rheum Dis; 2023 Sep; 26(9):1770-1778. PubMed ID: 37431263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gout: state of the art after a decade of developments.
    Pascart T; Lioté F
    Rheumatology (Oxford); 2019 Jan; 58(1):27-44. PubMed ID: 29547895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Febuxostat compared with allopurinol in patients with hyperuricemia and gout.
    Becker MA; Schumacher HR; Wortmann RL; MacDonald PA; Eustace D; Palo WA; Streit J; Joseph-Ridge N
    N Engl J Med; 2005 Dec; 353(23):2450-61. PubMed ID: 16339094
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An allopurinol-controlled, multicenter, randomized, double-blind, parallel between-group, comparative study of febuxostat in Chinese patients with gout and hyperuricemia.
    Huang X; Du H; Gu J; Zhao D; Jiang L; Li X; Zuo X; Liu Y; Li Z; Li X; Zhu P; Li J; Zhang Z; Huang A; Zhang Y; Bao C
    Int J Rheum Dis; 2014 Jul; 17(6):679-86. PubMed ID: 24467549
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of persistence rates between allopurinol and febuxostat as first-line urate-lowering therapy in patients with gout: an 8-year retrospective cohort study.
    Kim A; Kim Y; Kim GT; Ahn E; So MW; Lee SG
    Clin Rheumatol; 2020 Dec; 39(12):3769-3776. PubMed ID: 32458236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Febuxostat: a selective xanthine-oxidase/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout.
    Ernst ME; Fravel MA
    Clin Ther; 2009 Nov; 31(11):2503-18. PubMed ID: 20109996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of xanthine oxidase inhibitors on cardiovascular disease in patients with gout: a cohort study.
    Kim SC; Schneeweiss S; Choudhry N; Liu J; Glynn RJ; Solomon DH
    Am J Med; 2015 Jun; 128(6):653.e7-653.e16. PubMed ID: 25660249
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protocol of the Febuxostat versus Allopurinol Streamlined Trial (FAST): a large prospective, randomised, open, blinded endpoint study comparing the cardiovascular safety of allopurinol and febuxostat in the management of symptomatic hyperuricaemia.
    MacDonald TM; Ford I; Nuki G; Mackenzie IS; De Caterina R; Findlay E; Hallas J; Hawkey CJ; Ralston S; Walters M; Webster J; McMurray J; Perez Ruiz F; Jennings CG;
    BMJ Open; 2014 Jul; 4(7):e005354. PubMed ID: 25011991
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lesinurad: A Review in Hyperuricaemia of Gout.
    Deeks ED
    Drugs Aging; 2017 May; 34(5):401-410. PubMed ID: 28425024
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of treatment of hyperuricemic in patients admitted to the rheumatology ward and evaluation of compliance with the 2012 ACR Guidelines.
    Banse C; Fardellone P; Paccou J
    Joint Bone Spine; 2014 Oct; 81(5):461-2. PubMed ID: 24703403
    [No Abstract]   [Full Text] [Related]  

  • 19. Superiority of Low-Dose Benzbromarone to Low-Dose Febuxostat in a Prospective, Randomized Comparative Effectiveness Trial in Gout Patients With Renal Uric Acid Underexcretion.
    Yan F; Xue X; Lu J; Dalbeth N; Qi H; Yu Q; Wang C; Sun M; Cui L; Liu Z; He Y; Yuan X; Chen Y; Cheng X; Ma L; Li H; Ji A; Hu S; Ran Z; Terkeltaub R; Li C
    Arthritis Rheumatol; 2022 Dec; 74(12):2015-2023. PubMed ID: 35795968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of febuxostat versus allopurinol and the predictors of achieving target serum urate in a cohort of Thai people with gout.
    Lertnawapan R; Jatuworapruk K
    Clin Rheumatol; 2021 Jan; 40(1):255-262. PubMed ID: 32607660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.